Immunosuppressive monoclonal antibodies: Current and next generation

Clinical Microbiology and Infection

Volumn 17, Issue 12, 2011, Pages 1759-1768

  Focosi, D ^a   Maggi, F ^b   Pistello, M ^b   Boggi, U ^a   Scatena, F ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Antibody; Immunosuppression; Infectious diseases; Monoclonal antibody; Opportunistic infections

Indexed keywords

ABATACEPT; ADALIMUMAB; AIN 457; ALA ALA; ALEFACEPT; ALEMTUZUMAB; APOLIZUMAB; APRIL IG; BASILIXIMAB; BELATACEPT; BELIMUMAB; BRENTUXIMAB VEDOTIN; BRIAKINUMAB; CANAKINUMAB; CAT 8015; CD52 ANTIGEN; CERTOLIZUMAB PEGOL; CINQUIL; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DACETUZUMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; EPRATUZUMAB; ETANERCEPT; FRESOLIMUMAB; GALIXIMAB; GAVILIMOMAB; GOLIMUMAB; IBRITUMOMAB TIUXETAN; IMMU 114; IMMU LL2; IMMUNO MEDICS; IMMUNOGLOBULIN; IMMUNOTOXIN LMB2; INFLIXIMAB; INOLIMOMAB; IRATUMUMAB; KELIXIMAB; LUMILIXIMAB; LYMPHOCYDE; METELIMUMAB; MNL 0002; MOGAMULIZUMAB; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; OBINUTUZUMAB; OCRELIZUMAB; OFATUMUMAB; OKT 3; OMALIZUMAB; ONCOLYM; OTELIXIZUMAB; PASCOLIZUMAB; PLACEBO; RILONACEPT; RITUXIMAB; RUPLIZUMAB; SAR 3419; SGN 30; SIPLIZUMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VELTUZUMAB; VISILIZUMAB; ZAMYL; ZANOLIMUMAB;

ACUTE GRAFT REJECTION; ANKYLOSING SPONDYLITIS; ANTI NEUTROPHIL CYSTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS; ANTIBODY STRUCTURE; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; COLD AGGLUTININ SYNDROME; CROHN DISEASE; CRYOGLOBULINEMIA; CYTOMEGALOVIRUS INFECTION; DERMATOMYOSITIS; DRUG MECHANISM; DRUG MEGADOSE; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRAVES DISEASE; HEMOPHILIA A; HEPATITIS B; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN DEFICIENCY; INFECTION; INFECTION RATE; INFECTION RISK; KIDNEY GRAFT REJECTION; LIVER GRAFT REJECTION; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MEMBRANOUS GLOMERULONEPHRITIS; MULTIPLE SCLEROSIS; MYCOSIS; MYELOOPTIC NEUROPATHY; NEISSERIACEAE INFECTION; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OPSOCLONUS MYOCLONUS SYNDROME; ORGANIZING PNEUMONIA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PEMPHIGUS VULGARIS; PNEUMOCYSTIS PNEUMONIA; PREVENTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIASIS VULGARIS; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; STREPTOCOCCUS INFECTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUBERCULOSIS; ULCERATIVE COLITIS; VASCULITIS; VIRUS INFECTION;

EID: 81255160986     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03677.x     Document Type: Review

References (98)

1. Clifford D, Deluca A, Simpson D, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9: 438-446.
2. Eastwood D, Findlay L, Poole S et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 2010; 161: 512-526.
3. Pastan I, Ondam M, Weldon J, Fitzgerald D, Kreitman R. Immunotoxins with decreased immunogenicity and improved activity. Leuk Lymphoma 2011; 52(Suppl 2): 87-90.
4. Kadin M, Vonderheid E. Targeted therapies: denileukin diftitox-a step towards a 'magic bullet' for CTCL. Nat Rev Clin Oncol 2010; 7: 430-432.
5. Galloway JB, Hyrich KL, Mercer LK et al. The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2011; 50: 1341-1342.
6. Gürcan H, Keskin D, Stern J, Nitzberg M, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009; 9: 10-25.
7. Díaz-Lagares C, Pérez-Alvarez R, García-Hernández F et al. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther 2011; 13: R112.
8. Carson K, Evens A, Richey E et al. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the research on adverse drug event and reports (RADAR) project. Blood 2009; 113: 4834-4840.
9. Tydén G, Genberg H, Tollemar J, Ekberg H, Persson N, Tufveson G. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87: 1325-1329.
10. Kamar N, Milioto O, Puissant-Lubrano B, Esposito L, Pierre MC, Mohamed A. Incidence and predictive factors for infectious diseases after rituximab therapy in kidney transplant patients. Am J Transplant 2010; 10: 89-98.
11. Shelton E, Yong MC, Cohney S. Late onset pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology 2009; 14: 696-699.
12. Bitzan M, Ouahed J, Carpineta L, Bernard C, Bell L. Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease. Pediatr Nephrol 2010; 25: 1163-1167.
13. Kamar N, Mengelle C, Rostaing L. Incidence of JC-virus replication after rituximab therapy in solid organ transplant patients. Am J Transplant 2009; 9: 244-245.
14. Koo Y, Tay M, Teh Y et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol 2011; 90: 1219-1223.
15. Ennishi D, Maeda Y, Niitsu N et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010; 116: 5119-5125.
16. Tesfa D, Ajeganova S, Hägglund H et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B-lymphocyte depletion and infections. Arthritis Rheum 2011; 63: 2209-2214.
17. Diwakar L, Gorrie S, Richter A et al. Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol 2010; 63: 275-277.
18. Anolik J, Friedberg J, Zheng B et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 2007; 122: 139-145.
19. Silva L, Ortigosa LC, Benard G. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2010; 2: 817-833.
20. Singh J, Wells G, Christensen R et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; 2: CD008794.
21. Tubach F, Salmon D, Ravaud P et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60: 1884-1894.
22. Charpin C, Guis S, Colson P et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009; 11: R179.
23. Rosen H, Shackleton C, Higa L, Grainek I, Farmer D, McDiarmid S. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92: 1453-1457.
24. Everson G. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002; 8: 19-27.
25. Swinnen L, Costanzo-Nordin M, Fisher SG, O'Sullivan E, Johnson M, Heroux A. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723-1728.
26. Abbott K, Hypolite I, Poropatich R, Hshieh P, Cruess D, Hawkes C. Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis 2001; 3: 203-211.
27. Hibberd P, Tolkoff-Rubin N, Cosimi A, Schooley R, Isaacson D, Doran M. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992; 53: 68-72.
28. Oh C, Stratta R, Fox B, Sollinger H, Belzer F, Maki D. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. Transplantation 1988; 45: 68-73.
29. Thistlethwaite J, Stuart J, Mayes J, Gaber A, Woodle S, Buckingham M. Complications and monitoring of OKT3 therapy. Am J Kidney Dis 1988; 11: 112-119.
30. Chatenoud L, Bluestone J. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7: 622-632.
31. Campara M, Tzvetanov I, Oberholzer J. Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation. Expert Opin Biol Ther 2010; 10: 959-969.
32. Nashan B, Light S, Hardie I, Lin A, Johnson J. Reduction of acute renal allograft rejection by daclizumab. Daclizumab double therapy study group. Transplant 1999; 67: 110-115.
33. Hengster P, Pescovitz M, Hyatt D, Mergreiter R. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche study group. Transplant 1999; 68: 310-313.
34. Nashan B, Moore R, Amlot P, Schmidt A, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 international study group. Lancet 1997; 350: 1193-1198.
35. Neuhaus P, Clavien P, Kittur D, Salizzoni M, Rimola A, Abeywickrama K. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002; 8: 132-142.
36. Filipponi F, Callea F, Salizzoni M, Grazi GL, Fassati L, Rossi M. Double-blind comparison of hepatitis C histological recurrence rate in HCV+ liver transplant recipients given basiliximab+steroids or basiliximab+placebo, in addition to cyclosporine and azathioprine. Transplantation 2004; 78: 1488-1495.
37. Llado L, Fabregat J, Castellote J, Ramos E, Xiol X, Torras J. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl 2008; 14: 1752-1760.
38. Marubashi S, Dono K, Amano K, Hama N, Gotoh K, Takahashi H. Steroid-free living-donor liver transplantation in adults. Clin Transplant 2005; 80: 704-706.
39. Tan H, Kaczorowski D, Basu A, McCauley J, Marcos A, Donaldson J. Steroid-free tacrolimus monotherapy after pretransplantation RATG or campath and laparoscopy in living donor renal transplantation. Transplant Proc 2005; 37: 4235-4240.
40. Margreiter R, Klempnauer J, Neuhaus P, Muehlbacher F, Boesmueller C, Calne R. Alemtuzumab (campath-1h) and tacrolimus monotherapy after renal transplantation:results of a prospective randomized trial. Am J Transplant 2008; 8: 1480-1485.
41. Vallejo C, Ríos E, de la Serna J et al. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab. Expert Rev Hematol 2011; 4: 9-16.
42. Khraishi M, Russel A, Olszynski W. Safety profile of abatacept in rheumatoid arthritis: a review. Clin Ther 2010; 32: 1855-1870.
43. Larse CP, Grinyó J, Medina-Pestana J et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010; 90: 1528-1535.
44. Bluestone J, Liu W, Yabu J, Laszig Z, Putnam A, Belingheri M. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 10: 2086-2096.
45. Talamonti M, Spallone G, Di Stefani A, Costanzo A, Chimenti S. Efalizumab. Expert Opin Drug Saf 2011; 10: 239-251.
46. Chaarani J, Lebwohl M. Alefacept: where it stands today. Expert Opin Drug Metab Toxicol 2010; 6: 355-361.
47. Woodruff T, Nandakumar K, Tedesco F. Inhibiting the C5-C5a receptor axis. Mol Immunol 2011; 48: 1631-1642.
48. Leonard J, Goldenberg D. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 2007; 26: 3704-3713.
49. Sanz I, Yasothan U, Kirkpatrick P. Belimumab. Nat Rev Drug Discov 2011; 10: 335-336.
50. Bannwarth B, Richez C. Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf 2011; 10: 123-131.
51. Di Domenico M, Bisogno A, Polverino M, De Rosa C, Ricci V, Capasso A. Xolair in asthma therapy: an overview. Inflamm Allergy Drug Targets 2011; 10: 2-12.
52. Reinisch W, de Villiers W, Bene L et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010; 16: 233-242.
53. Trachtman H, Fervenza FC, Gipson D et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 2011; 79: 1236-1243.
54. Bonafoux D, Lee WC. Strategies for TGF-beta modulation: a review of recent patents. Expert Opin Ther Pat 2009; 19: 1759-1769.
55. Kuemmerle-Deschner J, Ramos E, Blank N et al. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res Ther 2011; 13: R34.
56. Hart T, Blackburn M, Brigham-Burke M et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002; 130: 93-100.
57. Smith D, Minthorn E, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet 2011; 50: 215-227.
58. Walsh G. Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. Curr Opin Mol Ther 2009; 11: 329-336.
59. Kurzeja M, Rudnicka L, Olszewska M. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol 2011; 12: 113-125.
60. Ding C, Li J, Zhang X. Bertilimumab. Cambridge Antibody Technology Group. Curr Opin Investig Drugs 2004; 5: 1213-1218.
61. Atlizumab: anti-IL-6 receptor antibody-chugai. BioDrugs 2003; 17: 369-372.
62. Langley R, Papp K, Bissonnette R et al. Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies. Int J Dermatol 2010; 49: 818-828.
63. Sharma A, Davis C, Tobia L et al. Free full text comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther 2000; 293: 33-41.
64. Taylor P. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 2003; 3: 323-328.
65. Kim Y, Duvic M, Obitz E et al. Clinical efficacy of zanolimumab (humax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007; 109: 4655-4662.
66. Henslee-Downey P, Parrish R, MacDonald J et al. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. Transplantation 1996; 61: 738-734.
67. Spillner J, Kohnle M, Albrecht K, Heemann U. Anti-LFA-1 monoclonal antibody in renal transplantation: renal function, infections, and other complications. Transplant Proc 1998; 30: 2163.
68. McLaughlin P, Grillo-Lopez A, Link B, Levy R, Czuczman M, Williams M. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
69. Vugmeyster Y, Beyer J, Howell K. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in macaca fascicularis. J Immunother 2005; 28: 212-219.
70. Bayes M, Rabasseda X, Prous J. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2007; 29: 231-245.
71. Stein R, Qu Z, Chen S et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004; 10: 2868-2878.
72. Umana P, Moessner E, Bruenker P et al. Novel 3rd generation humanized type II CD20 antibody with glycoengineered fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. Blood. 2006; 108: Abstract no. 229.
73. Srinivasan A, Mukherji S. Tositumomab and iodine I 131 tositumomab (bexaar). AJNR Am J Neuroradiol 2011; 32: 637-638.
74. Vose J, Bierman P, Loberiza FJ, Bociek R, Matso D, Armitage J. Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma 2007; 48: 683-690.
75. Lamonica D, Czuczman M, Nabi H, Klippenstein D, Grossman Z. Radioimmunoscintigraphy (RIS) with bectumomab (Tc99m labeled IMMU-ll2, lymphoscan) in the assessment of recurrent non-Hodgkin's lymphoma (NHL). Cancer Biother Radiopharm 2002; 17: 689-697.
76. DiJoseph J, Dougher M, Kalyandrug L et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 2006; 12: 242-249.
77. Byrd J, Castro J, O'Brien S. Comparison of results from a phaseI/II study of lumiliximab (anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR results. Blood. 2006; 108: Abstract no. 32.
78. Wahl A, Klussman K, Thompson J et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002; 62: 3736-3742.
79. Ansell S, Horwitz S, Engert A et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25: 2764-2769.
80. Foyil K, Bartlett NL. Brentuximab vedotin for the treatment of CD30+ lymphomas. Immunotherapy 2011; 3: 475-485.
81. Sievers E, Linenberger M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol 2001; 13: 522-527.
82. Jurcic J, DeBlasio T, Dumont L, Yao T, Scheinberg D. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HUM195 in acute promyelocytic leukemia. Clin Cancer Res 2000; 6: 372-380.
83. Hussein M, Berenson J, Niesvizky R et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 2010; 95: 845-848.
84. Skarica M, Eckstein C, Whartenby KA, Calabresi P. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J Neuroimmunol 2011; 235: 70-76.
85. Tilg H, Kaser A. Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease. Curr Opin Investig Drugs 2010; 11: 1295-1304.
86. Dyer M. The role of campath-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 1999; 26: 52-57.
87. Ricart A. Immunoconjugates against solid tumors: mind the gap. Clin Pharmacol Ther 2011; 89: 513-523.
88. Seekamp A, van Griensven M, Dhondt E et al. The effect of anti-l-selectin (aselizumab) in multiple traumatized patients-results of a phase II clinical trial. Crit Care Med 2004; 32: 2021-2028.
89. Czuczman M, Thall A, Witzig T. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005; 23: 4390-4398.
90. Macmillan M, Couriel D, Weisdorf D et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 2007; 109: 2657-2662.
91. Nakamura M, Tanaka Y, Satoh T et al. Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism. Rheumatology (Oxford) 2006; 45: 150-156.
92. Antoniu S. Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Curr Opin Mol Ther 2010; 12: 770-779.
93. Rech J, Repp R, Rech D et al. A humanized HLA-DR antibody (HU1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study. Leuk Lymphoma 2006; 47: 2147-2154.
94. Nagy Z, Hubner B, Lohning C et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med 2002; 8: 801-807.
95. Stein R, Qu Z, Chen S, Solis D, Hansen H, Goldenberg D. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood 2006; 108: 2736-2744.
96. Martin S, Tichy E, Gabardi S. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation. Pharmacotherapy 2011; 31: 394-407.
97. Rossi J. Phase I study of atacicept in relapsed/refractory multiple myeloma (MM) and Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11: 136-138.
98. Dubois E, Rissmann R, Cohen A. Rilonacept and canakinumab. Br J Clin Pharmacol 2011; 71: 639-641.